SCHEMBL1633440

SCHEMBL1633440

CNC(=O)Cc1cccc(Nc2ncc3cccc(OC4CCN(C(C)C)CC4)c3n2)c1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 3/20 0.53
JAK1 P23458 3/20 0.53
TYK2 P29597 3/20 0.53
JAK3 P52333 3/20 0.53
TNIK Q9UKE5 1/20 0.46
PTK2 Q05397 3/20 0.43
SCN9A Q15858 6/20 0.42
AURKA O14965 2/20 0.41
CDK4 P11802 1/20 0.41
CDK2 P24941 2/20 0.39
NEK2 P51955 1/20 0.39
NTRK1 P04629 1/20 0.39
CCNA2 P20248 1/20 0.39
CCNA1 P78396 1/20 0.39
SLC5A7 Q9GZV3 1/20 0.38
GFRA2 O00451 1/20 0.38
GFRA3 O60609 1/20 0.38
GFRA1 P56159 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1632762 0.97 JAK2 (0.50) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1631185 0.94 JAK2 (0.53) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1633921 0.92 JAK2 (0.54) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1632967 0.91 JAK2 (0.53) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1632763 0.88 JAK2 (0.45) JAK2JAK1TYK2JAK3TNIK
SCHEMBL13498328 0.88 JAK2 (0.49) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1634256 0.85 JAK2 (0.54) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1633776 0.84 JAK2 (0.59) JAK2JAK1TYK2JAK3TNIK
SCHEMBL13498290 0.83 JAK2 (0.54) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1632367 0.83 JAK2 (0.55) JAK2JAK1TYK2JAK3TNIK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed